Here is a list of stocks with an above 10% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Eli Lilly and Company

13.7% sales growth and 131.77% return on equity

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide.

Eli Lilly and Company’s sales growth this year is expected to be 9.3% and 12.3% for next year.

Year-on-year quarterly revenue growth grew by 4.8%, now sitting on 23.21B for the twelve trailing months.

Eli Lilly and Company’s sales growth for the next quarter is 13.7%. The company’s growth estimates for the current quarter and the next is 35.8% and 13.1%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 131.77%.

Volatility

Eli Lilly and Company’s last day, last week, and last month’s average volatility was a positive 0.35%, a negative 0.29%, and a positive 0.53%, respectively.

Eli Lilly and Company’s last day, last week, and last month’s high and low average amplitude percentage was 1.35%, 2.66%, and 2.34%, respectively.

Eli Lilly and Company’s Stock Yearly Top and Bottom Value

Eli Lilly and Company’s stock is valued at $166.41 at 19:22 EST, under its 52-week high of $173.90 and way higher than its 52-week low of $117.06.

Eli Lilly and Company’s Moving Average

Eli Lilly and Company’s value is higher than its 50-day moving average of $158.00 and above its 200-day moving average of $152.89.

2. Generac Holdlings Inc.

33.2% sales growth and 25.53% return on equity

Generac Holdings Inc. designs, manufactures, and sells power generation equipment, energy storage systems, and other power products for the residential, and light commercial and industrial markets worldwide.

Generac Holdlings Inc.’s sales growth this year is anticipated to be 11.4% and 17.9% for next year.

Year-on-year quarterly revenue growth grew by 16.7%, now sitting on 2.32B for the twelve trailing months.

Generac Holdlings Inc.’s sales growth for the next quarter is 33.2%. The company’s growth estimates for the current quarter and the next is 28.8% and 73.6%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 25.53%.

Volatility

Generac Holdlings Inc.’s last day, last week, and last month’s average volatility was 5.79%, 0.53%, and 0.95%, respectively.

Generac Holdlings Inc.’s last day, last week, and last month’s high and low average amplitude percentage was 5.33%, 3.20%, and 4.08%, respectively.

Generac Holdlings Inc.’s Stock Yearly Top and Bottom Value

Generac Holdlings Inc.’s stock is valued at $265.75 at 19:22 EST, below its 52-week high of $269.98 and way higher than its 52-week low of $75.50.

Generac Holdlings Inc.’s Moving Average

Generac Holdlings Inc.’s value is way above its 50-day moving average of $229.67 and way above its 200-day moving average of $195.72.

3. Veeva Systems Inc.

25.1% sales growth and 18.73% return on equity

Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, the Middle East, Africa, and Latin America.

Veeva Systems Inc.’s sales growth this year is expected to be 31.2% and 18.6% for next year.

Year-on-year quarterly revenue growth grew by 34.4%, now sitting on 1.38B for the twelve trailing months.

Veeva Systems Inc.’s sales growth for the next quarter is 25.1%. The company’s growth estimates for the present quarter and the next is 25.9% and 10.6%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.73%.

Volatility

Veeva Systems Inc.’s last day, last week, and last month’s average volatility was 4.06%, 1.18%, and 0.33%, respectively.

Veeva Systems Inc.’s last day, last week, and last month’s high and low average amplitude percentage was 3.89%, 3.17%, and 3.34%, respectively.

Veeva Systems Inc.’s Stock Yearly Top and Bottom Value

Veeva Systems Inc.’s stock is valued at $288.54 at 19:22 EST, below its 52-week high of $313.99 and way higher than its 52-week low of $118.11.

Veeva Systems Inc.’s Moving Average

Veeva Systems Inc.’s worth is higher than its 50-day moving average of $273.73 and higher than its 200-day moving average of $270.44.

4. Sapiens International Corporation N.V.

15.6% sales growth and 13.91% return on equity

Sapiens International Corporation N.V. provides software solutions for the insurance and financial services industries in North America, Europe, the Asia Pacific, and South Africa.

Sapiens International Corporation N.V.’s sales growth this year is expected to be 17.3% and 10.2% for next year.

Year-on-year quarterly revenue growth grew by 18.2%, now sitting on 367.96M for the twelve trailing months.

Sapiens International Corporation N.V.’s sales growth for the next quarter is 15.6%. The company’s growth estimates for the ongoing quarter and the next is 19% and 20%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.91%.

Volatility

Sapiens International Corporation N.V.’s last day, last week, and last month’s average volatility was 0.52%, 0.61%, and 0.60%, respectively.

Sapiens International Corporation N.V.’s last day, last week, and last month’s high and low average amplitude percentage was 2.72%, 2.65%, and 2.78%, respectively.

Sapiens International Corporation N.V.’s Stock Yearly Top and Bottom Value

Sapiens International Corporation N.V.’s stock is valued at $31.64 at 19:22 EST, way under its 52-week high of $35.23 and way above its 52-week low of $13.55.

Sapiens International Corporation N.V.’s Moving Average

Sapiens International Corporation N.V.’s value is higher than its 50-day moving average of $29.26 and higher than its 200-day moving average of $29.96.

5. Blueprint Medicines Corporation

407.9% sales growth and 36.29% return on equity

Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in genomically defined cancers, rare diseases, and cancer immunotherapy.

Blueprint Medicines Corporation’s sales growth this year is expected to be 1084% and a negative 80.7% for next year.

Year-on-year quarterly revenue growth grew by 8053.2%, now sitting on 811.16M for the twelve trailing months.

Blueprint Medicines Corporation’s sales growth for the next quarter is 407.9%. The company’s growth estimates for the ongoing quarter and the next is a negative 20.7% and 21.8%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 36.29%.

Volatility

Blueprint Medicines Corporation’s last day, last week, and last month’s average volatility was a positive 0.21%, a positive 0.96%, and a negative 0.28%, respectively.

Blueprint Medicines Corporation’s last day, last week, and last month’s high and low average amplitude percentage was 4.76%, 5.72%, and 4.42%, respectively.

Blueprint Medicines Corporation’s Stock Yearly Top and Bottom Value

Blueprint Medicines Corporation’s stock is valued at $107.22 at 19:22 EST, way below its 52-week high of $125.61 and way higher than its 52-week low of $43.29.

Blueprint Medicines Corporation’s Moving Average

Blueprint Medicines Corporation’s worth is under its 50-day moving average of $111.64 and way above its 200-day moving average of $91.74.

6. Vmware, Inc.

11% sales growth and 22.16% return on equity

VMware, Inc. provides software in the areas of hybrid cloud, multi-cloud, modern applications, networking and security, and digital workspaces in the United States and internationally.

Vmware, Inc.’s sales growth this year is expected to be 8.3% and 8.5% for next year.

Year-on-year quarterly revenue growth grew by 7.8%, now sitting on 11.55B for the twelve trailing months.

Vmware, Inc.’s sales growth for the next quarter is 11%. The company’s growth estimates for the current quarter and the next is a negative 0% and negative -2.6%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.16%.

Volatility

Vmware, Inc.’s last day, last week, and last month’s average volatility was a negative 0.83%, a positive 0.38%, and a positive 0.02%, respectively.

Vmware, Inc.’s last day, last week, and last month’s high and low average amplitude percentage was 2.95%, 2.85%, and 2.79%, respectively.

Vmware, Inc.’s Stock Yearly Top and Bottom Value

Vmware, Inc.’s stock is valued at $142.86 at 19:22 EST, way under its 52-week high of $163.17 and way above its 52-week low of $86.00.

Vmware, Inc.’s Moving Average

Vmware, Inc.’s worth is above its 50-day moving average of $142.23 and below its 200-day moving average of $142.90.

LEAVE A REPLY

Please enter your comment!
Please enter your name here